VX5
VX5 is a humanized IgG1κ monoclonal antibody inhibitor targeting BCA-1/CXCL13. VX5 significantly inhibits human CXCL13-mediated internalization of CXCR5, blocks both human and mouse CXCL13-dependent B-cells chemotaxis and migration (EC50s for 105 and 253 nM for human tonsillar and pre-B-697-hCXCR5 cells, respectively) . VX5 can be used to study autoimmune diseases like multiple sclerosis and arthritis, and cancers like gastric lymphomas and colon cancer[1].
Product Specifications
Product Name Alternative
VX5/5261
UNSPSC
12352203
Target
CXCR
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Purity
96.19
References & Citations
[1]Klimatcheva E, et al. Anti-cxcl13 antibodies and associated epitope sequences. US20160002325A1. 2016-01-07.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
CERCAM, CT (CERCAM, CEECAM1, GLT25D3, KIAA1502, Glycosyltransferase 25 family member 3, Cerebral endothelial cell adhesion molecule) (PE) discontinued